Key result
Elevated T-cell PDCD4 is linked to NVAF, and its inhibition suppresses inflammatory cytokines.
Why the study?
The immune and inflammatory mechanisms underlying non-valvular atrial fibrillation (NVAF) are not fully understood, and the regulatory role of PDCD4 in peripheral blood T lymphocyte responses in NVAF patients had not been assessed.
Is PDCD4 expression upregulated in peripheral T-cell subsets of patients with non-valvular atrial fibrillation, and does in vitro PDCD4 inhibition attenuate T-cell activation and proinflammatory cytokine secretion?
Case-Control (n=200)
No
Is PDCD4 expression upregulated in peripheral T-cell subsets of patients with non-valvular atrial fibrillation, and does in vitro PDCD4 inhibition attenuate T-cell activation and proinflammatory cytokine secretion?
PDCD4 is upregulated in peripheral T-cell subsets of patients with non-valvular atrial fibrillation and promotes T-cell activation and proinflammatory cytokine secretion, identifying PDCD4 as a potential immunomodulatory target in AF.
Answers are grounded in this paper and cite their sources.
PDCD4 upregulation in NVAF T cells may promote inflammation; hypothesis-generating for immunomodulatory targeting pending prospective validation.
The immune and inflammatory mechanisms underlying non-valvular atrial fibrillation (NVAF) are not fully understood. Programmed cell death 4 (PDCD4) is a transcriptional and translational inhibitor associated with pro-inflammatory activity and fibrotic remodeling in cardiac tissues. This study assessed the regulatory role of PDCD4 in T lymphocyte responses in the peripheral blood of NVAF patients. We utilized an open single-cell transcriptome dataset containing peripheral blood mononuclear cell samples from patients with drug-related paroxysmal atrial fibrillation during the medication period and the withdrawal period, combined with bioinformatics analysis, to preliminarily explore the role of PDCD4 in inflammatory response, cytokine secretion, and immune regulation. We collected peripheral blood from patients and matched non-AF controls and performed flow cytometry to (1) quantify PDCD4 expression in T-cell subsets, (2) determine the percentage of cytokine-positive PDCD4 + and PDCD4– T cells, and (3) quantify the expression of surface co-stimulatory and co-inhibitory receptors after in vitro stimulation with or without PDCD4-IN-1. T cell vitality was measured using the CCK-8 assay, and cytokine secretion was assessed by ELISA. Single-cell transcriptome analysis revealed that PDCD4 was highly expressed in activated CD8 + T cells from AF group. PDCD4-expressing cells exhibited strong enrichment for T-cell receptor signaling, cytokine–cytokine receptor interaction, and complement activation. Flow cytometry showed that PDCD4 expression was significantly higher in CD4 + T cells, CD8 + T cells, and Treg cells in the NVAF group (all P < 0.001). The secretion of IL-4, IL-17 A, IL-10, and IFN-γ was significantly higher in PDCD4 + T cells than in PDCD4 − T cells ( P < 0.05). PDCD4 inhibition reduced the percentage of CD8 + CD137 + T cells ( P < 0.001), T cell vitality ( P < 0.01), and the secretion of the proinflammatory cytokines IFN-γ and TNF-α ( P < 0.001). PDCD4 affects the immune microenvironment in NVAF by promoting peripheral T cell activation, and inflammatory cytokine secretion.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a case-control in Non-valvular atrial fibrillation (NVAF) (n=200). Non-valvular atrial fibrillation (PDCD4 expression and in vitro PDCD4-IN-1 inhibition) vs. Matched non-AF controls (and DMSO vehicle control for in vitro experiments) was evaluated on Peripheral blood PDCD4 expression in CD4+ T cells, CD8+ T cells, and CD25+CD127- Treg cells (p=<0.001). PDCD4 expression was elevated in CD4+, CD8+, and Treg cells of NVAF patients, and PDCD4 inhibition reduced CD8+CD137+ T cells and IFN-γ/TNF-α secretion.
Synapse has enriched 10 related papers. Consider them for comparative context: